Investor Conference Call presentation

FY22 Te Whakatakotoranga ki nga
Kaiwhakangao o ngā Otinga ā Tau
FY22 Annual Results Investor Presentation
30 August 2022

Rua Bioscience Limited (Rua) is a New Zealand pharmaceutical company aiming to be a
leading producer of cannabinoid derived medicines. This presentation and the information
contained in or accompanying this presentation are not, and are under no circumstances to
be construed as, an invitation to subscribe for, or an offer of, shares, securities or financial
products to any person, in any country or the basis for a contract, financial advice, other
advice or recommendation to conclude any transaction for the purchase or sale of any
security, loan or other instrument. This presentation has not been independently
verified.Neither Rua nor any of its directors, officers, shareholders, advisors, agents or
employees make any representation or warranty as to the accuracy or completeness of the
information contained in this presentation and those parties shall have no liability for any
statement, opinion, information or matters arising out of, contained in, or for any omissions
from, or failure to correct or update any information in, this presentation or any other
communications transmitted to you in relation to this presentation.
2

Rob Mitchell
Kaiwhakahāere Matua
Chief Executive Officer
Hamish White
ĀpihaKaiwhakahāerePūtea
Chief Financial Officer
3

Anna Stove
Kaiwhakahāere Ringatohu
Managing Director
Panapa Ehau
Kaiwhakaū / Ringatohu
Executive Director, Co-Founder
4

Tirohanga Whānui
Overview
•Operational Achievements
•Key Appointments
•Financial Highlights
•Outlook
5

In FY22, Rua focused on preparing for market entry –securing the partners and
developing the frameworks and strategies that will give the company the best
chance of success both at home and abroad.
By the close of FY22, Rua launched its first product in New Zealand and established
an end-to-end cultivation and supply solution that is both at scale and scalable.
Tirohanga Whānui
FY22: An Overview
6

7
September 2021
Achieved GMP certification
December 2021
Green light to distribute first product in
New Zealand
Welcomed the East Coast Cannabis
Company (E3C).
January 2022
Shareholders approve Zalm Therapeutics
acquisition
April 2022
First medicine launched in New Zealand
June 2022
Narcotics licence received to distribute
and market products in Germany
Mawhiti mai ki nga
Whakatutukitanga
Achievements at a Glance

Te Whakaterenga o te Hua Tuatahi
o Rua ki ngaTūroro kei Aotearoa
Rua LaunchesFirstProductfor
NewZealandPatients
8
The launch of Rua’s first medicine in
Aotearoa was a milestone for New Zealand
patients, prescribers, and the medicinal
cannabis industry.
Rua will launch a range of new medicines in
FY23.
The product launch was complemented by
the launch of our compassionate access
programme.

Te Kōkiritanga a Rua ki te Mākete o Tiāmana
Rua Significantly Advances German Market Entry
9
In June, Rua received its narcotic license
through Nimbus Health for the distribution
and marketing of its first product for the
German medicinal cannabis market –a
move understood to make Rua the first
medicinal cannabis company from New
Zealand to take such a step.
The approval of the application will enable
Nimbus to distribute and market Rua's
products in Germany by the end of the
calendar year 2022.

Te WhakawhanakeWhakatupuo teKāinga
Developing Local Cultivation Capacity
10
Rua’s indoor cultivation team continues to
establish the unique varieties which Rua
will be able to grow at scale in Cann’s
GMP-certified facility at Mildura .
Rua also welcomed E3C as its first local
cultivation partner in December.

TeWhakawhanakeHuanga heiRatongaki ngāMāketeo te
Ao Whānui
Developing Production Capacity to Service Further Global
Markets
11
Photo Credit: Cann Group
In January 2022, shareholders overwhelmingly
approved the purchase of Zalm.
Critical to the acquisition, Rua secured access to
Zalm’s third-party supply contract for GMP-grade
medicinal cannabis with Australian producer Cann
Group.
This has set the stage to accelerate market entry
and expand patient choice and enabled Rua to
advance relationships in other high-growth markets
including the Czech Republic, Poland and the UK.

Developing Local Cultivation Capacity
Ruatorea, New Zealand
12
Rua’s indoor cultivation team has focused on
genetic export readiness by continuing to
establish the commercially viable varieties we
will use to create world-class medicines. With
access to Cann’s cultivation facility secured,
our team has been focused on developing
unique East Coast genetics, which we expect
to grow at scale at Mildura.
Rua also welcomed E3C as its first local
cultivation partner in December.
Whakangaoatuki nga
Kaupapa Hou WhaiHua
Investing in Innovation
Across the Value Chain
R&D is important for Rua as the company
looks to develop medicinal cannabis
products that are unique to the global
market.
During the year, Rua received an initial
$376,000 grant from Callaghan Innovation
to underpin its $1.3m research project.
Projects currently being worked on relate to
plant science and product development.

TeWhānauo Rua –Nga Toa Āheitangao teAo
Our People –World-class Capability
SUSAN MARTINDALEDR JACK CHAN
Production Manager
PhD in Pharmacy from the University of
Otago
Master of Pharmacy (Hons) University of
Strathclyde (UK),
MBA from the University Sains Malaysia.
Comes to Rua Production from
pharmacist for Malaysian
Pharmaceutical Industries, later as
Senior Pharmacist at B. Braun Medical
Industries Malaysia.
Head of Regulatory Affairs
a lifetime of experience in regulatory
affairs spanning New Zealand, Australia
and Europe. Held various regulatory,
advisory and management positions
within the Ministry of Health, including
chairing the Ministerial advisory
committee responsible for medicines
classification.
AMY QUATTLEBAUM
Quality Control Analyst
Studied biochemistry at the University
of North Carolina, USA, where she
gained her Masters of Science (MSc).
Comes it Rua from Lanzatech in
Chicago, where she was the analytical
quality assurance lead.
13

Rua’sannualfinancialresultsforthe
year the ended 30 June 2022.
Nga Pūtea
Financial Highlights
Profit & Loss
Investment in R&D $2.98m
Loss before tax for the year ended
30 June 2022 was $7.49m
Total income $646k
14

Cash, CashEquivalentsand Investments
$9.94m
Rua’sannualfinancialresultsforthe
year the ended 30 June 2022.
Nga Pūtea
Financial Highlights
Balance Sheet
15
Total Assets $33.57m
Total Liabilities $9.38m
Net Assets of $24.2m

Rua’sannualfinancialresultsforthe
year the ended 30 June 2022.
Nga Pūtea
Financial Highlights
Cashflow
16
Netcashoutflowfromfinancing
activities$209k
Netcashoutflowfromoperating
activities$6.84m
Net cash inflow from investing
activities $5.59m

Te TirohangaWhānuio teMākete
o Aotearoa
Outlook for the NZ Market
FY22 saw the realisation of commercialisation
milestones for Rua with regulatory approvals
enabling the production and subsequent New
Zealand launch of Rua’s first product, a CBD oil.
Rua will build on this success in FY23, increasing
the volumes and range of medicines it delivers to
New Zealand patients.
The company’s commercial team has a solid
strategy to grow market share, develop its product
portfolio and engage Rua’s prescriber base.
17

Te TirohangaWhānuiki ngaMāketeki
Tāwāhi
Outlook for Export Markets
Rua expects to enter the
German market via its supply
agreement with Nimbus
Health.
Rua will explore business
opportunities with parties in
the Czech Republic, Poland
and the United Kingdom.
Rua expects to advance the
five-year agreement with
Motagon, giving Rua the first
opportunity to supply the
European distributor with a full
portfolio of medicines.
18

10:00am
12 October, 2022
Waikanae Surf Club, Gisborne and online.
Nau maiki tehui āTau
Join us for the AGM
19

FY22 Te Whakatakotoranga ki nga
Kaiwhakangao o ngā Otinga ā Tau
FY22 Annual Results Investor Presentation
30 August 2022